On June 17, 2023, Nymox Pharmaceutical Corporation terminated the employment of each of Mr. Christopher R. Riley, Chief Financial Officer. The Company has initiated a search for a Chief Financial Officer, and is in the process of hiring a general counsel to assume the role of Mr. Lanham.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 USD | -3.57% | -10.00% | -54.24% |
1st Jan change | Capi. | |
---|---|---|
-54.24% | 25.21M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- NYMXF Stock
- News Nymox Pharmaceutical Corporation
- Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer